CA-TIGO
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the launch of the GO EV Charger for the Italian market. A smart residential electric vehicle (EV) charging station, GO EV Charger offers solar installers a way to add e-mobility that seamlessly integrates with the Tigo EI (Energy Intelligence) Residential Solar Solution, which includes inverter, battery system, TS4 MLPE devices, and everything else required for fast, flexible, and dependable solar installations. The Tigo EI Residential Solar Solution will be on display from February 28th to March 1st at KEY - The Energy Transition Expo in Rimini, Italy.
Previously released for the German market, the GO EV Charger features seamless integration with the Tigo EI Residential solar-plus-storage solution. The GO EV Charger is available in single- or three-phase variants, up to 22 kW, and delivers high flexibility with multiple charging modes, current limits, and scheduling options. In addition to integrated RFID for authorized-user identification, end-users can manage the GO EV Charger remotely through the Tigo Energy Intelligence (EI) app. The Tigo Energy Intelligence platform also provides powerful commissioning, monitoring, and fleet management functions for installers. The Tigo GO EV Charger features a protective enclosure for indoor or outdoor installation and a 60-month warranty.
“We take pride in providing our customers with a system that not only delivers high performance, ease of use, and reliability but empowers us on the installer side to provide outstanding support remotely,” said Quinto Ferri, Owner of Ferri Quinto & C. s.n.c. “We rely on the Tigo EI Residential solution because it is designed to enable faster installation and commissioning, thus allowing our customers to benefit from solar energy sooner. We also understand that every customer's energy requirements are unique, so the flexibility offered by Tigo's solar-plus-storage solution allows us to provide bespoke solutions that cater to each individual's needs and help them achieve their specific energy goals.”
“Solar installers like Quinto lead the way in sustainable home energy in Italy, and with a record of multiple Tigo EI Residential systems already deployed, Ferri Quinto & C. s.n.c. has repeatedly demonstrated their ability to design winning unique solutions that meet customer needs,” said Mirko Bindi, Senior VP Sales EMEA & MD Europe at Tigo Energy. “Exciting times ahead as we unveil a captivating array of innovative solutions, further enriching our products and services our installations partners can offer their customers. As the stack of Tigo EI Residential products expands with options like EV charging, homeowners benefit from a home energy system that optimizes production and consumption, enabling the best possible return on investment.”
In the European market, the Tigo EI Residential Solar Solution now includes the Tigo GO EV Charger as well as Tigo TS4 Flex MLPE products, single-phase and three-phase Tigo inverters, modular DC-coupled Tigo energy storage components, and the Tigo EI Link device. The Tigo TS4 platform is a fundamental building block for solar systems of all sizes and significantly increases energy production by mitigating the impact of shading and module mismatch, providing first-responder safety with rapid shutdown, and enabling system performance insights through module-level monitoring. With module-level monitoring, Tigo EI software processes energy data from the EI Residential System, allowing system owners to manage and monitor energy and installers to monitor and manage their fleets of customer systems efficiently. Since 2007, Tigo has deployed 3.5 GW of Tigo MLPE devices across more than 100 countries on all seven continents, of which Tigo Energy Intelligence monitors more than 1 GWh of daily solar production.
Learn more about Tigo solutions at KEY – The Energy Transition Expo (Quartiere Fieristico di Rimini, Italy, Pav. D1, Booth 001) from February 28th to March 1st. Please use this link to schedule a meeting with a Tigo representative or view the list of Tigo partners exhibiting at the event.
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221652197/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Approximately 7% of people in the United States (U.S.) have atopic dermatitis – a common, chronic, and flaring inflammatory skin disease, characterized by persistent itch and recurrent skin lesions1-4 While currently available treatments may improve some signs and symptoms of the disease, many patients do not respond optimally to approved therapies and do not experience itch relief and clear skin to the same degree2,5-7 Nemluvio® (nemolizumab) is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and epidermal dysregulation in atopic dermatitis2,9-11 This approval follows Nemluvio’s recent approval for the treatment of adults with prurigo nodularis from the U.S. Food and Drug Administration earlier in August 202412 Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug
Andersen Global forstærker sin dækning af Asien-Stillehavsregionen med ejendomsrådgivere i Australien13.12.2024 19:39:00 CET | Pressemeddelelse
Andersen Global styrker sin platform i Asien og Stillehavsregionen gennem en samarbejdsaftale med Charter Keck Cramer, der er et af Australiens førende, uafhængige ejendomsrådgivningsfirmaer. Det, der i 1970 begyndte som en lille virksomhed, Charter Keck Cramer, har siden udviklet sig til et tværfagligt firma med mere end 170 eksperter, der er fordelt på fem kontorer i Australien og Singapore. Firmaet tilbyder et omfattende udvalg af ejendomsrelaterede ydelser, herunder værdiansættelser inden for bolig- og erhvervsejendomme, ejendoms- og udviklingsrådgivning, ejendomsdata og analyser samt strategisk planlægning og byøkonomi samt kvantitetsopmåling. Charter Keck Cramer betjener en mangfoldig australsk og international kundebase, herunder offentlige og private virksomheder, ejere og udviklere, større banker og finansielle institutioner, institutionelle ejere og truster, statslige organer og familiekontorer. "Vores vækst over de seneste 54 år er drevet af vores uafhængige, skræddersyede t
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press release
Businesses Must Employ a Multi-Layered Approach to Fight GenAI Fraud Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unli
Capcom Announces Onimusha Way of the Sword, Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom